Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Christian R. Frey"'
2
Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection
Autor: Elisa Bono, Francis V. Chisari, Valeria Fumagalli, Valentina Venzin, Pietro Di Lucia, Robert Jordan, William Delaney, Matteo Iannacone, Luca G. Guidotti, Christian R. Frey
Publikováno v: The Journal of Experimental Medicine
Antibody-mediated clearance of circulating HBsAg has minimal impact on the expansion of HBV-specific CD8+ T cells undergoing intrahepatic priming. It does not alter their differentiation into dysfunctional cells, nor does it enhance their functional
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7952baf1cd3d80a9da164eff51f35230
http://europepmc.org/articles/PMC7596822
Zobrazit plný text záznamu
3
PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection
Autor: Simon P. Fletcher, Christian R. Frey, Magdeleine Hung, Nina Le Bert, Patrick T F Kennedy, Loghman Salimzadeh, Antonio Bertoletti, Nikolai Novikov, Evan W. Newell, Charles-A. Dutertre, Upkar S. Gill
Publikováno v: Journal of Clinical Investigation. 128:4573-4587
Chronic HBV (CHB) infection suppresses virus-specific T cells, but its impact on humoral immunity has been poorly analyzed. Here, we developed a dual-staining method that utilizes hepatitis B virus (HBV) surface antigens (HBsAg) labeled with fluoroch
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45762c58d7ea2f01d7c08e142fe9c31e
https://doi.org/10.1172/jci121957
Zobrazit plný text záznamu
6
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors
Autor: Rujuta A. Bam, Luong Tsai, Kirsten M. Stray, Madeleine Willkom, Gabriel Birkus, Tomas Cihlar, Christian R. Frey, Stephen R. Yant
Publikováno v: Antimicrobial Agents and Chemotherapy. 60:316-322
Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV). Previous studies suggested a principal role for the lysosomal serine protease cathepsin A (CatA) in the in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e847c93d1018d75dd66f963ec56336
https://doi.org/10.1128/aac.01834-15
Zobrazit plný text záznamu
7
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
Autor: Tomas Cihlar, Andrew Mulato, Derek Hansen, Joseph Hesselgesser, Rujuta A. Bam, Alivelu Irrinki, Stephen R. Yant, Gregg S. Jones, Christian R. Frey
Publikováno v: Antimicrobial Agents and Chemotherapy
GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic infection and transiently activated HIV exp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed99910500a2eaae76627a1fcc88401
https://doi.org/10.1128/aac.01369-16
Zobrazit plný text záznamu
8
Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses
Autor: Daniel B. Tumas, Joseph Hesselgesser, Christian R. Frey, Randall L. Halcomb, Jim Zheng, Abigail Fosdick, Stefan Pflanz, Grushenka H.I. Wolfgang
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 348:96-105
GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-molecule agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b786234674b209884a301105c9108609
https://doi.org/10.1124/jpet.113.207878
Zobrazit plný text záznamu
9
Antibody-dependent and antibody-independent uptake of HBsAg across human leucocyte subsets is similar between individuals with chronic hepatitis B virus infection and healthy donors
Autor: Robert Jordan, Stefan Pflanz, Indrani Rebbapragada, Christian R. Frey, Hugo Tharinger, Dharmaraj Samuel, Nikolai Novikov, Mindie H. Nguyen
Publikováno v: Journal of viral hepatitis. 24(6)
Maintaining detectable levels of antibodies to hepatitis B surface antigen (HBsAg) in serum after HBsAg sero-conversion is the key clinical endpoint indicative of recovery from infection with hepatitis B virus (HBV). As HBV-infected hepatocytes secre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135589c366e09f8235d0d985e7cb5278
https://pubmed.ncbi.nlm.nih.gov/28012213
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje